Global Gene Therapy Market Analysis, Phases, Key Company and Forecast to 2022

Global Gene Therapy Market Analysis & Forecast to 2022 research report provides Gene Therapy Phases, Strength of Gene Therapy Industry, Vectors for Gene Delivery, Clinical Applications, Key Company analysis and forecasts to 2022

Pune, India - November 14, 2018 /MarketersMedia/ —

In 2017, the gene therapy market for technologies, services and products was estimated to be worth $x million, with a potential to reach $363 million by 2022. The main market space is cancer which currently holds x% market share. This indication generated $x million in 2017 and will generate $x million in 2022. This is followed by rare diseases, cardiovascular, neurological and ocular indications. Looking at the market by technology, at present, gene product therapeutics generate the majority of revenue with over $x million in 2017, growing to $x million by 2022. Viral vectors are set to generate $x million in 2017, and will rise to $x million in 2022, and by then gene therapy services such as vector development and transfection will hit $x million. At present, the Americas have penetrated the market significantly with 65% geographic share, followed by Europe (x%) and the RoW (x%).

Company Profiles: 4d Molecular Therapeutics LLC, Abeona Therapeutics LLC, Advanced Cell & Gene Therapy LLC, Advantagene Inc., Adverum Biotechnologies Inc., Addgene Inc., Agilis Biotherapeutics LLC, Angionetics Inc., Applied Genetic Technologies Corporation (AGTC), AnGes MG Inc., Asklepios BioPharmaceutical Inc., Audentes Therapeutics Inc. and others…

Get Discount on Gene Therapy Market Analysis & Forecast to 2022 Report at https://www.reportsnreports.com/contacts/discount.aspx?name=1370259

This report provides the reader with:

• Current Global Market Worth and Forecast with CAGR Through 2022
• Sub-Market Worth by Therapeutic Area (Cancer, Rare Diseases, Cardiovascular, Neurological, Ocular) and Forecast with CAGR Through 2022
• Sub-Market Worth by Geography (Americas, Europe, RoW) and Forecast with CAGR Through 2022
• Sub-Market Worth by Technology (Gene Product, Service, Viral Vectors) and Forecast with CAGR Through 2022
• Insight into gene therapy technologies, challenges associated with developing therapeutic genes and disadvantages of gene therapy.
• Full outline of the gene therapy industry from the formative years through to products discovered during 1990 and 2017.
• Detailed descriptions of commercialized products approved between 2003 and 2017 that include: Gendicine, Rexin-G, Oncorine, Neovasculgen, Glybera, Imlygic, Strimvelis, Zalmoxis, Kymriah, Yescarta and Luxturna.
• Description of seven of the Phase III product candidates that include: Generx, Collategene, LentiGlobin, Lenti-D, VM-202, Invosa and GS-010.
• Description of 21 Phase II product candidates that are set to have significant market share.
• Commercialization status of gene therapies in by geographic region
• Evaluation of gene therapy pricing
• Description of the firstever warranty offer by GSK for Strimvelis.
• A detailed analysis of various types of viruses used as vectors.
• Description of clinical applications of gene therapy and the various genetic and infectious diseases addressed by gene therapy.
• Description of 77 companies that are directly and indirectly associated with gene therapy industry.

Order a Complete Research Study of Gene Therapy Market Report at https://www.reportsnreports.com/purchase.aspx?name=1370259

Key Questions Answered in this Report:

• What is the size of gene therapy market?
• What is the CAGR and market size over the next five years?
• What are the different sub-markets and their worth/CAGR over the next five years?
• What is gene augmentation therapy?
• What is suicide gene therapy?
• How is ex vivo gene delivery different from in vivo gene delivery?
• What are the types of gene therapies classified on the basis of targeted cell types?
• What is the role of CRISPR technology in gene therapy?
• What are the approved gene therapy products?
• How many gene therapy product candidates have reached the Phase III stage?
• How many Phase II gene therapy product candidates are there?
• What is the commercialization status of gene therapies in E.U. member countries?
• What are the prices of gene therapy products?
• What are the reasons for this extortionate pricing of gene therapies?
• Which company is offering warranty for its gene- therapy product?
• What is the current strength of gene therapy industry?
• Is it true that the real strength of gene therapy industry is based on the number of clinical trials?
• What is the total number of ongoing clinical trials as of 2017?
• What is the distribution of clinical trials by geography?
• Which countries are associated with gene therapy clinical trials?
• What are the major indications addressed by the clinical trials?
• Which genes are transferred in these clinical trials?
• How many Big Pharma are associated with the Gene Therapy Industry?
• What are non-viral and viral vectors?
• What are the various features of viral vectors?
• Which viral vectors are predominantly used in gene therapy clinical trials?
• What are the major diseases addressed by therapeutic genes?
• Where is the gene therapy market heading, and what opportunities and challenges will it face?

Table of Contents:
1.0 Introduction
2.0 Gene Therapy: The Basics
3.0 Historic Overview of Gene Therapy
4.0 Gene Therapy Phase III Product Candidates
5.0 Gene Therapy Phase II Product Candidates
6.0 Commercialization, Cost and Warranty of Gene Therapies
7.0 The Strength of Gene Therapy Industry
8.0 Vectors for Gene Delivery
9.0 Clinical Applications of Gene Therapy
10.0 Market Analysis
11.0 Manufacturing of Viral Vectors and Logistics
12.0 Company Profiles

Contact Info:
Name: Hrishikesh Patwardhan
Email: Send Email
Organization: ReportsnReports

Source URL: https://marketersmedia.com/global-gene-therapy-market-analysis-phases-key-company-and-forecast-to-2022/443554

For more information, please visit https://www.reportsnreports.com/reports/1370259-global-gene-therapy-market-analysis-forecast-to-2022.html

Source: MarketersMedia

Release ID: 443554

More News From sports.morningdispatcher.com

Pant helps Delhi eliminate Hyderabad from IPL

May 24, 2019

VISAKHAPATNAM, India — Rishabh Pant hit a blistering 49 off 21 balls as Delhi Capitals notched a thrilling two-wicket victory against Sunrisers Hyderabad in the Indian Premier League Eliminator on Wednesday. Pant smashed five sixes and two fours in Delhi's first IPL play-off in six years which carried them to 165-8 when Keemo Paul struck a winning boundary on the penultimate ball of their run-chase. Hyderabad had earlier scored 162-8 despite their two key players — Englishman Jonny Bairstow and Australian David Warner — being back with their respective national teams for World Cup preparations. "If you try to stop...

Czech international Sural killed in auto crash in Turkey

May 24, 2019

ANKARA, Turkey — Czech Republic international Josef Sural was killed and six other Alanyaspor players were injured on Monday when their van crashed on the way home from a Turkish league soccer match. The 28-year-old Sural died in the hospital during emergency surgery, Alanyaspor president Hasan Cavusoglu told NTV television by telephone. The six other players were reported to be in stable condition. Cavusoglu said Sural and his six teammates hired a private luxury van to return from a game at Kayserispor in central Turkey. The crash occurred near the entrance to the town of Alanya, on Turkey's Mediterranean coast....

Shadab Khan ruled out of series against England with illness

May 24, 2019

ISLAMABAD — Pakistan leg spinner Shadab Khan was ruled out of next month's one Twenty20 and five-match one-day international series against England due to illness on Sunday. Leg spinner Yasir Shah, who has taken 23 wickets in 24 ODIs, will replace Shadab for the series, which begins May 5 with the only Twenty20 game at Cardiff on May 5. The ODI series starts May 8. "The tests revealed a virus that will require treatment and rest for, at least, four week," the Pakistan Cricket Board said in a statement on Shadab. The PCB didn't reveal the exact nature of Shadab's...

Widows, ace guide to climb Everest to honor Sherpas

May 24, 2019

KATHMANDU, Nepal — Five years after one of the deadliest disasters on Mount Everest, three people from Nepal's ethnic Sherpa community are preparing an ascent to raise awareness about the Nepalese mountain guides who make it possible for hundreds of foreign climbers to scale the mountain and survive. Kami Rita, a renowned climber who lived through the 2014 ice avalanche on Everest's western shoulder that killed 16 fellow Sherpa guides, aims to break his own record by reaching the mountaintop a 23rd time this spring. Furdiki Sherpa, who lost her husband in a mountaineering accident, and Nima Doma, whose husband...

Mohammad Amir dropped from Pakistan's World Cup squad

May 24, 2019

ISLAMABAD — Pakistan dropped out-of-form fast bowler Mohammad Amir and included 18-year-old paceman Mohammad Hasnain in its 15-member World Cup squad on Thursday. Amir's exclusion came after the left-armer took only five wickets in 14 ODIs since Pakistan won the Champions Trophy in 2017. "Amir is the most experienced bowler but his performance was not good enough since the Champions Trophy," chief selector Inzamam-ul-Haq said. "Hasnain will be a surprise package as he bowls at a speed of 150 (kph) and could win a match for Pakistan on his own. With such an express pace he could put a dent...

About Us

Get all the up-to-date breaking news about politics, business, entertainment, sports, lifestyles, weather, traffic, and local news in a seamless digital environment only in Morning Dispatcher.

Contact us: sales[at]morningdispatcher.com

Subscribe Now!

Quick Links

HomePress